AgeX Therapeutics Inc (AGE)

AgeX Therapeutics Inc. is a biotechnology company that is focused on the development and commercialization of therapeutics targeting human aging and degenerative diseases. The Company's product pipeline includes two cell-based therapies, which is derived from telomerase-positive pluripotent stem cells (PSCs) and two product candidates, which is derived from its induced Tissue Regeneration (iTRTM) technology. The Company's AGEX-BAT1 is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. Its AGEX-VASC1 is designed to restore vascular support in aged ischemic tissues, such as the aging heart. The Company's iTRTM technology product candidates include AGEX-iTR1547, which is a drug-based formulation, and AGEX-iTR1550 (Renelon), which is a gene delivery technology.